Company Announcements - Jia Mei Packaging's stock price increased by 230% from December 17, 2025, to January 6, 2026, leading to a suspension for investigation starting January 7, 2026 [2] - Guosheng Technology's stock rose by 370.2% during the same period, prompting a suspension for investigation effective January 7, 2026 [3] - Fenglong Co., Ltd. indicated that it may apply for a suspension if its stock price continues to rise abnormally [4] - Xinfang Pharmaceutical is facing public prosecution for alleged unit bribery [7] - Shengke Communication's second-largest shareholder plans to reduce its stake by no more than 3% [8] - Chip Origin Technology completed the acquisition of Zhudian Semiconductor [9] - Robotech's subsidiary signed a significant contract for automatic optical switch packaging with a Swiss client [10] - Aerospace Changfeng clarified that it does not engage in brain-computer interface or commercial aerospace businesses [12] - Chengjian Development holds 18.91 million shares of Century Space, making it the fourth-largest shareholder [13] - Sanbo Brain Science is not involved in the research, production, or sales of brain-computer interface products [14] - Weisi Medical's new products in the brain-computer interface field are still in the early market cultivation stage [16] - Mairande's products in the brain-computer interface area are also in the research and market cultivation phase [17] - Guankang Technology plans to acquire 100% of Liaojing Electronics, with stock resuming trading [19] - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Star Chain to expand its presence in the brain-computer interface field [20] - China Satellite Communications warned that its stock price is at a historical high and may experience a significant drop [21] - Beidou Star Communication stated that commercial aerospace is just one application scenario for its products and services [22] Financial Performance - Lier Chemical expects a net profit increase of 113.62% to 132.19% for 2025 [39] - Zhongtai Co., Ltd. anticipates a net profit of 420 million to 480 million yuan for 2025, recovering from a previous loss [38] Financing and Capital Increase - Desai Xiwai is planning to issue H-shares and list on the Hong Kong Stock Exchange [40] - Xingye Yinx is also preparing to issue H-shares for listing on the Hong Kong Stock Exchange [41] Other Significant Events - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a shareholding increase commitment [42] - *ST Changyao's stock may face termination of listing due to negative net assets and other financial issues [43]

资金流向方面，该股今日全天主力资金净流入149.61万元。（数据宝） 1月6日伟思医疗（688580）收盘价69.70元，收盘涨停，全天换手率10.74%，振幅9.09%，成交额6.98亿 元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 伟思医疗1月6日龙虎榜 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.72亿元， 其中，买入成交额为7562.98 万元，卖出成交额为9590.80万元，合计净卖出2027.82万元。具体来看，今日上榜营业部中，第一大买 入营业部为高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部，买入金额为2382.30万元， 其次是摩根大通证券(中国)有限公司上海银城中路证券营业部，买入金额1522.09万元。卖出营业部中， 卖出金额居首的是国泰海通证券股份有限公司大同向阳街证券营业部，卖出金额为3505.09万元。 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 2382.30 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1522. ...

Core Insights - The brain-computer interface (BCI) industry is transitioning from "scientific experiments" to "commercialization," with Neuralink planning large-scale production by 2026, igniting market expectations [1] - China is accelerating its progress in the BCI field through supportive policies and technological breakthroughs, with significant investments being made in the sector [1][12] - The market is characterized as a "0 to 1" incremental market, driven by short-term sentiment from Neuralink's production expectations and favorable domestic policies [1] Investment Landscape - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest funding round in the BCI sector after Neuralink [1] - Investors are advised to focus on companies with core technological advantages, such as self-developed chips and flexible electrodes, as well as those that can achieve commercial closure in rehabilitation and consumer electronics [1] Technology Comparison - The BCI technology landscape is divided into invasive, semi-invasive, and non-invasive routes, each with distinct differences in signal quality, safety, and commercialization timelines [2] - Invasive methods, like those used by Neuralink, involve surgical implantation of electrodes for high-resolution signal acquisition but come with high costs and long development cycles [5] - Non-invasive methods utilize external sensors for signal collection, offering lower costs and safety but facing challenges with signal attenuation [8] Competitive Landscape - The U.S. leads in invasive BCI technology by 2-5 years, while China is catching up, particularly in non-invasive applications where both countries are on par [9][11] - Chinese companies are making significant strides in clinical trials, with several achieving notable milestones in both invasive and non-invasive technologies [12] Company Developments - Companies like BrainCo and Huashan Hospital have completed pioneering clinical trials in invasive BCI systems, demonstrating the ability to control devices through thought [12][13] - Strong Brain Technology has received FDA and CE certifications, positioning itself as a leader in the commercialization of BCI products [12] - Other companies, such as Beijing Chip Intelligence and ZhiDian Medical, are also advancing in the invasive BCI space, with various clinical trials and product developments underway [13][14] Regulatory Environment - The Chinese government has included BCI in its national strategic emerging industries, with plans for independent billing standards and industry regulations to facilitate commercialization [11]

智通财经APP讯，伟思医疗(688580.SH)发布股价异动公告称，公司主营业务聚焦于康复医疗器械的研 发、生产与销售，产品广泛应用于精神康复、盆底及产后康复、神经康复等领域。截至2025年末，公司 在脑机接口领域的新产品仍处于市场培育初期，主要布局非侵入式技术路线，与当前国际领先的侵入式 脑机接口存在显著技术路径差异，相关产品尚未实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

(本文来自第一财经) 伟思医疗发布异动公告称，公司主营业务聚焦于康复医疗器械的研发、生产与销售，产品广泛应用于精 神康复、盆底及产后康复、神经康复等领域。截至2025年末，公司在脑机接口领域的新产品仍处于市场 培育初期，主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接口存在显著技术路径差异，相 关产品尚未实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

南方财经1月6日电，伟思医疗(688580)1月6日公告，公司股票连续三个交易日内（2025年12月31日、 2026年1月5日、1月6日）收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动。经公司自查，确 认不存在关于公司的应披露而未披露的重大事项，公司目前生产经营正常。截至2025年末，公司在脑机 接口领域的新产品仍处于市场培育初期，主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接 口存在显著技术路径差异，相关产品尚未实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2026-001 南京伟思医疗科技股份有限公司 股票交易异常波动公告 一、股票交易异常波动的具体情况 公司股票连续三个交易日内（2025 年 12 月 31 日、2026 年 1 月 5 日、1 月 6 日）收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所科创板股票异常 交易实时监控细则》的有关规定，属于股票交易异常波动的情形。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●南京伟思医疗科技股份有限公司（以下简称"公司"）股票连续三个交易 日内（2025年12月31日、2026年1月5日、1月6日）收盘价格涨幅偏离值累计超过 30%，属于股票交易异常波动。 ●经公司自查，截至本公告披露日，确认不存在关于公司的应披露而未披露 的重大事项，公司目前生产经营正常，生产经营未发生重大变化。 ●公司主营业务聚焦于康复医疗器械的研发、生产与销售，产品广泛应用于 精神康复、盆底及产后康复、神经康复等领域。截至 2025 年末，公司在脑机接 口领域的新产 ...

人民财讯1月6日电，伟思医疗(688580)1月6日公告，公司股票连续三个交易日内(2025年12月31日、2026 年1月5日、1月6日)收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动。经公司自查，确认不 存在关于公司的应披露而未披露的重大事项，公司目前生产经营正常。截至2025年末，公司在脑机接口 领域的新产品仍处于市场培育初期，主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接口存 在显著技术路径差异，相关产品尚未实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

格隆汇1月6日丨伟思医疗(688580.SH)公布，公司主营业务聚焦于康复医疗器械的研发、生产与销售， 产品广泛应用于精神康复、盆底及产后康复、神经康复等领域。截至2025年末，公司在脑机接口领域的 新产品仍处于市场培育初期，主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接口存在显著 技术路径差异，相关产品尚未实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days in late December 2025 and early January 2026, but there are no undisclosed significant matters affecting its operations [1] Financial Performance - As of the end of 2025, the company's new brain-computer interface products are in the early stages of market cultivation and have not yet achieved large-scale sales, contributing limited revenue [1] - For the first three quarters of 2025, the company reported revenue of 326 million yuan, representing a year-on-year increase of 11.58% [1] - The net profit for the same period was 102 million yuan, reflecting a year-on-year growth of 30.68% [1] Investor Advisory - The company has reminded investors to be cautious and to consider risks when investing [1]